| Alectinib studied in …STUDIED_INderived61 of 61show fewer |
|---|
| → studied in | NCT04302025Phase 2 · recruiting A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06862869recruiting Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04589845Phase 2 · active not recruiting Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study · 61 trials list this drug (28 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03178552Phase 2/Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06765109Phase 3 · recruiting Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06624059Phase 3 · completed A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04774718Phase 1/Phase 2 · active not recruiting A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors · 61 trials list this drug (28 active) | — | — | Central Nervous System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05170204Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03768063Phase 3 · active not recruiting A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study · 61 trials list this drug (28 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03445000Phase 2 · terminated ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04116541Phase 2 · recruiting A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. · 61 trials list this drug (28 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05722886Phase 2/Phase 3 · recruiting DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol · 61 trials list this drug (28 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02838420Phase 3 · completed A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) · 61 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05525858recruiting KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II · 61 trials list this drug (28 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03194893Phase 3 · completed A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer · 61 trials list this drug (28 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02075840Phase 3 · completed A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07001384Phase 1 · recruiting A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) · 61 trials list this drug (28 active) | — | — | Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07560410Phase 1/Phase 2 · not yet recruiting Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) · 61 trials list this drug (28 active) | — | — | Malignant Bone Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03202940Phase 1/Phase 2 · active not recruiting A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314481Phase 2 · completed Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737994Phase 2 · terminated Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer · 61 trials list this drug (28 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987644Phase 1/Phase 2 · recruiting Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements · 61 trials list this drug (28 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05770037Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers · 61 trials list this drug (28 active) | — | — | Neoplasm by Site,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 61 trials list this drug (28 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03596866Phase 3 · completed A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer · 61 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04341181Phase 2 · recruiting ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling · 61 trials list this drug (28 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02521051Phase 1/Phase 2 · terminated Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834348completed A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423185Phase 2 · recruiting PLATFORM Study of Precision Medicine for Rare Tumors · 61 trials list this drug (28 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03944772Phase 2 · active not recruiting Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551521Phase 2 · completed CRAFT: The NCT-PMO-1602 Phase II Trial · 61 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04632992Phase 2 · completed A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response · 61 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06709274NA · not yet recruiting Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 61 trials list this drug (28 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04322890Phase 2 · recruiting Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04351334completed Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05015010Phase 2 · active not recruiting Alectinib in Neo-adjuvant Treatment of Stage III NSCLC · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532149recruiting ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02091141Phase 2 · completed My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors · 61 trials list this drug (28 active) | — | — | Neoplasm,Solid Neoplasm,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03546894completed A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05159245Phase 2 · recruiting The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs · 61 trials list this drug (28 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05525338Phase 4 · recruiting Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels · 61 trials list this drug (28 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06339554completed Alectinib-induced Endocrine Toxicity · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 61 trials list this drug (28 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 61 trials list this drug (28 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05081674Phase 2 · completed Brazilian Lung Immunotherapy Study · 61 trials list this drug (28 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 61 trials list this drug (28 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03158389Phase 1/Phase 2 · completed NCT Neuro Master Match - N²M² (NOA-20) · 61 trials list this drug (28 active) | — | — | Adult Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04644315Phase 2 · terminated A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors · 61 trials list this drug (28 active) | — | — | Neoplasm,Neoplasm by Site,Digestive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03779191Phase 2 · completed Alectinib in Combination With Bevacizumab in ALK Positive NSCLC · 61 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647110completed Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. · 61 trials list this drug (28 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05725200Phase 2 · recruiting Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · 61 trials list this drug (28 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03271554completed Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03131206Phase 1/Phase 2 · terminated A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer · 61 trials list this drug (28 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma,RET-Positive Lung Non-Small Cell Carcinoma,RET-Positive Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04708639unknown Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients · 61 trials list this drug (28 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02013219Phase 1 · completed A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155009Phase 2 · completed A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02604342Phase 3 · completed Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01801111Phase 1/Phase 2 · completed A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01871805Phase 1/Phase 2 · completed A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02271139no longer available Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy · 61 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |